Radiodermatitis - Global ﾂ鮓ｹﾔｭｴｴ Outlook (2017-2026)

Publication ID:

SMRC0518056

Publication Date:

May 1, 2018

Pages:

148

Publisher:

Stratistics MRC

Countries:

Global [1]

USD 4,150.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

The Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ is accounted for $318.9 million in 2017 and expected to grow at a CAGR of 4.8% to reach $489.8 million by 2026. Factor such as the large size of patient pool, increasing obesity, unhealthy habits like usage of tobacco and increasing demand for radiation-based chemotherapy are fueling the market growth. Discovery of equipment of radiation therapies such as intensity-modulated radiation therapy (IMRT) and proton therapy are hindering the market growth. Rise in research and developments, clinical trials, and product development through partnerships and collaborations with medical institutions provide ample opportunities to the market.
By distribution channel, Retail pharmacy which provides prescription drugs, among other products and has many customers depending on them because of its features like easy availability and affordability. It has the capability of controlling the stock on hands, participation in pharmacy benefit management (PBM) networks, advising the customers to buy the drugs & suggest prescriptions and having better financial & debt management with the customer are the driving factors for the consumers to depend on retail pharmacy stores.
Based on product, the topical product has key benefits such as reduce the risk of microbial transmission, protect the skin against abrasive materials, easy application, availability, are considered to be the major factors resulting in adoption of these products. Corticosteroids, hydrophilic creams, and topical antibiotics are some of the major products under this segment. Corticosteroids agents are considered as a better standard in the treatment of inflammatory skin conditions, thereby increasing in adoption for the treatment of radiodermatitis.
Asia Pacific region has dominated the market, due to its huge population base. In addition, extensive collaborations, established pharmaceutical companies in this region are extensively involved in the promotion of their products and usage amongst the end users and supporting government initiatives supporting research activities and increased deployment of products are the key factors propelling market growth in this region. North America held the second largest share of the radiodermatitis market and driven by high R&D investment deployed by global players.
Some of the key players in the market are 3M, ConvaTec Inc., Stratpharma AG, BMG Pharma S.R.L., Acelity, Derma Sciences, Inc., Smith & Nephew plc, Intermed Pharmaceuticals and Molnlycke Health Care AB.
Distribution Channels covered:
窶｢ Online Pharmacy
窶｢ Retail Pharmacy
窶｢ Hospital Pharmacy

Products Covered:
窶｢ Oral Drugs
窶｢ Dressings
窶｢ Topical

Regions Covered:
窶｢ North America
o US
o Canada
o Mexico
窶｢ Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
窶｢ Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
窶｢ South America
o Argentina
o Brazil
o Chile
o Rest of South America
窶｢ Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- ﾂ鮓ｹﾔｭｴｴ share assessments for the regional and country level segments
- ﾂ鮓ｹﾔｭｴｴ share analysis of the top industry players
- Strategic recommendations for the new entrants
- ﾂ鮓ｹﾔｭｴｴ forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- ﾂ鮓ｹﾔｭｴｴ Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Table Of Contents:

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 ﾂ鮓ｹﾔｭｴｴ Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Emerging ﾂ鮓ｹﾔｭｴｴs
3.8 Futuristic ﾂ鮓ｹﾔｭｴｴ Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ, By Distribution Channel
5.1 Introduction
5.2 Online Pharmacy
5.3 Retail Pharmacy
5.4 Hospital Pharmacy

6 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ, By Product
6.1 Introduction
6.2 Oral Drugs
6.2.1 Analgesics
6.3 Dressings
6.3.1 No Sting Barrier Film
6.3.2 Silicone Coated Dressing
6.3.3 Hydrocolloid
6.3.4 Honey Impregnated Gauze
6.3.5 Hydrogel
6.3.6 Other Dressings
6.3.6.1 GM-CSF gauze
6.3.6.2 Silver Leaf Dressing
6.4 Topical
6.4.1 Hydrophilic creams
6.4.2 Corticosteroids
6.4.3 Antibiotics
6.4.4 Other Topicals

7 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa

8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 Company Profiling
9.1 3M
9.2 ConvaTec Inc.
9.3 Stratpharma AG
9.4 BMG Pharma S.R.L.
9.5 Acelity
9.6 Derma Sciences, Inc.
9.7 Smith & Nephew plc
9.8 Intermed Pharmaceuticals
9.9 Molnlycke Health Care AB

List of Tables
Table 1 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Region (2016-2026) ($MN)
Table 2 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Distribution Channel (2016-2026) ($MN)
Table 3 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Online Pharmacy (2016-2026) ($MN)
Table 4 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Retail Pharmacy (2016-2026) ($MN)
Table 5 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospital Pharmacy (2016-2026) ($MN)
Table 6 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Product (2016-2026) ($MN)
Table 7 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Drugs (2016-2026) ($MN)
Table 8 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Analgesics (2016-2026) ($MN)
Table 9 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Dressings (2016-2026) ($MN)
Table 10 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By No Sting Barrier Film (2016-2026) ($MN)
Table 11 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silicone Coated Dressing (2016-2026) ($MN)
Table 12 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrocolloid (2016-2026) ($MN)
Table 13 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Honey Impregnated Gauze (2016-2026) ($MN)
Table 14 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrogel (2016-2026) ($MN)
Table 15 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Dressings (2016-2026) ($MN)
Table 16 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By GM-CSF gauze (2016-2026) ($MN)
Table 17 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silver Leaf Dressing (2016-2026) ($MN)
Table 18 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Topical (2016-2026) ($MN)
Table 19 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrophilic creams (2016-2026) ($MN)
Table 20 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Corticosteroids (2016-2026) ($MN)
Table 21 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Antibiotics (2016-2026) ($MN)
Table 22 Global Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Topicals (2016-2026) ($MN)
Table 23 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) ($MN)
Table 24 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Distribution Channel (2016-2026) ($MN)
Table 25 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Online Pharmacy (2016-2026) ($MN)
Table 26 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Retail Pharmacy (2016-2026) ($MN)
Table 27 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospital Pharmacy (2016-2026) ($MN)
Table 28 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Product (2016-2026) ($MN)
Table 29 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Drugs (2016-2026) ($MN)
Table 30 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Analgesics (2016-2026) ($MN)
Table 31 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Dressings (2016-2026) ($MN)
Table 32 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By No Sting Barrier Film (2016-2026) ($MN)
Table 33 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silicone Coated Dressing (2016-2026) ($MN)
Table 34 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrocolloid (2016-2026) ($MN)
Table 35 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Honey Impregnated Gauze (2016-2026) ($MN)
Table 36 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrogel (2016-2026) ($MN)
Table 37 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Dressings (2016-2026) ($MN)
Table 38 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By GM-CSF gauze (2016-2026) ($MN)
Table 39 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silver Leaf Dressing (2016-2026) ($MN)
Table 40 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Topical (2016-2026) ($MN)
Table 41 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrophilic creams (2016-2026) ($MN)
Table 42 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Corticosteroids (2016-2026) ($MN)
Table 43 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Antibiotics (2016-2026) ($MN)
Table 44 North America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Topicals (2016-2026) ($MN)
Table 45 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) ($MN)
Table 46 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Distribution Channel (2016-2026) ($MN)
Table 47 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Online Pharmacy (2016-2026) ($MN)
Table 48 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Retail Pharmacy (2016-2026) ($MN)
Table 49 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospital Pharmacy (2016-2026) ($MN)
Table 50 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Product (2016-2026) ($MN)
Table 51 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Drugs (2016-2026) ($MN)
Table 52 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Analgesics (2016-2026) ($MN)
Table 53 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Dressings (2016-2026) ($MN)
Table 54 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By No Sting Barrier Film (2016-2026) ($MN)
Table 55 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silicone Coated Dressing (2016-2026) ($MN)
Table 56 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrocolloid (2016-2026) ($MN)
Table 57 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Honey Impregnated Gauze (2016-2026) ($MN)
Table 58 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrogel (2016-2026) ($MN)
Table 59 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Dressings (2016-2026) ($MN)
Table 60 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By GM-CSF gauze (2016-2026) ($MN)
Table 61 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silver Leaf Dressing (2016-2026) ($MN)
Table 62 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Topical (2016-2026) ($MN)
Table 63 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrophilic creams (2016-2026) ($MN)
Table 64 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Corticosteroids (2016-2026) ($MN)
Table 65 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Antibiotics (2016-2026) ($MN)
Table 66 Europe Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Topicals (2016-2026) ($MN)
Table 67 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) ($MN)
Table 68 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Distribution Channel (2016-2026) ($MN)
Table 69 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Online Pharmacy (2016-2026) ($MN)
Table 70 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Retail Pharmacy (2016-2026) ($MN)
Table 71 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospital Pharmacy (2016-2026) ($MN)
Table 72 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Product (2016-2026) ($MN)
Table 73 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Drugs (2016-2026) ($MN)
Table 74 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Analgesics (2016-2026) ($MN)
Table 75 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Dressings (2016-2026) ($MN)
Table 76 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By No Sting Barrier Film (2016-2026) ($MN)
Table 77 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silicone Coated Dressing (2016-2026) ($MN)
Table 78 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrocolloid (2016-2026) ($MN)
Table 79 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Honey Impregnated Gauze (2016-2026) ($MN)
Table 80 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrogel (2016-2026) ($MN)
Table 81 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Dressings (2016-2026) ($MN)
Table 82 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By GM-CSF gauze (2016-2026) ($MN)
Table 83 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silver Leaf Dressing (2016-2026) ($MN)
Table 84 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Topical (2016-2026) ($MN)
Table 85 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrophilic creams (2016-2026) ($MN)
Table 86 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Corticosteroids (2016-2026) ($MN)
Table 87 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Antibiotics (2016-2026) ($MN)
Table 88 Asia Pacific Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Topicals (2016-2026) ($MN)
Table 89 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) ($MN)
Table 90 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Distribution Channel (2016-2026) ($MN)
Table 91 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Online Pharmacy (2016-2026) ($MN)
Table 92 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Retail Pharmacy (2016-2026) ($MN)
Table 93 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospital Pharmacy (2016-2026) ($MN)
Table 94 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Product (2016-2026) ($MN)
Table 95 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Drugs (2016-2026) ($MN)
Table 96 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Analgesics (2016-2026) ($MN)
Table 97 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Dressings (2016-2026) ($MN)
Table 98 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By No Sting Barrier Film (2016-2026) ($MN)
Table 99 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silicone Coated Dressing (2016-2026) ($MN)
Table 100 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrocolloid (2016-2026) ($MN)
Table 101 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Honey Impregnated Gauze (2016-2026) ($MN)
Table 102 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrogel (2016-2026) ($MN)
Table 103 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Dressings (2016-2026) ($MN)
Table 104 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By GM-CSF gauze (2016-2026) ($MN)
Table 105 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silver Leaf Dressing (2016-2026) ($MN)
Table 106 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Topical (2016-2026) ($MN)
Table 107 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrophilic creams (2016-2026) ($MN)
Table 108 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Corticosteroids (2016-2026) ($MN)
Table 109 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Antibiotics (2016-2026) ($MN)
Table 110 South America Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Topicals (2016-2026) ($MN)
Table 111 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) ($MN)
Table 112 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Distribution Channel (2016-2026) ($MN)
Table 113 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Online Pharmacy (2016-2026) ($MN)
Table 114 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Retail Pharmacy (2016-2026) ($MN)
Table 115 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hospital Pharmacy (2016-2026) ($MN)
Table 116 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Product (2016-2026) ($MN)
Table 117 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Oral Drugs (2016-2026) ($MN)
Table 118 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Analgesics (2016-2026) ($MN)
Table 119 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Dressings (2016-2026) ($MN)
Table 120 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By No Sting Barrier Film (2016-2026) ($MN)
Table 121 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silicone Coated Dressing (2016-2026) ($MN)
Table 122 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrocolloid (2016-2026) ($MN)
Table 123 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Honey Impregnated Gauze (2016-2026) ($MN)
Table 124 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrogel (2016-2026) ($MN)
Table 125 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Dressings (2016-2026) ($MN)
Table 126 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By GM-CSF gauze (2016-2026) ($MN)
Table 127 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Silver Leaf Dressing (2016-2026) ($MN)
Table 128 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Topical (2016-2026) ($MN)
Table 129 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Hydrophilic creams (2016-2026) ($MN)
Table 130 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Corticosteroids (2016-2026) ($MN)
Table 131 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Antibiotics (2016-2026) ($MN)
Table 132 Middle East and Africa Radiodermatitis ﾂ鮓ｹﾔｭｴｴ Outlook, By Other Topicals (2016-2026) ($MN)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.